AbbVie Inc.
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Lupron (leuprolide) [legacy through FY21] by Year
Lupron (leuprolide) [legacy through FY21] — International net revenues ($M) ($M)
AbbVie Lupron (leuprolide) [legacy through FY21]: $179M in FY2021, up 17.8% from a year earlier. No newer figure appears in the documents we track.
Where the FY2021 figure comes from
Source: Form 10-K (filed 2022-02-18) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Lupron (leuprolide) [legacy through FY21] — International net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2021 | Dec 31, 2021 | 179 | +17.8% | Form 10-K (filed 2022-02-18) ↗ |
| FY2020 | Dec 31, 2020 | 152 | -9.0% | Form 10-K (filed 2022-02-18) ↗ |
| FY2019 | Dec 31, 2019 | 167 | +0.6% | Form 10-K (filed 2022-02-18) ↗ |
| FY2018 | Dec 31, 2018 | 166 | +3.8% | Form 10-K (filed 2021-02-19) ↗ |
| FY2017 | Dec 31, 2017 | 160 | +1.3% | Form 10-K (filed 2020-02-21) ↗ |
| FY2016 | Dec 31, 2016 | 158 | – | Form 10-K (filed 2019-02-27) ↗ |
Breakdown
What makes up lupron (leuprolide) [legacy through FY21]
Cite this data
StockData. (2026). AbbVie Lupron (leuprolide) [legacy through FY21] ($M), annual FY2016–FY2021 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/lupron-intl
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.